Alto Neuroscience, Inc. (ANRO)

Market Cap	68.23M
Revenue (ttm)	n/a
Net Income (ttm)	-61.43M
Shares Out	26.97M
EPS (ttm)	-2.50
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	192,852
Open	2.650
Previous Close	2.650
Day's Range	2.530 - 2.650
52-Week Range	2.530 - 18.350
Beta	n/a
Analysts	Strong Buy
Price Target	17.00 (+571.94%)
Earnings Date	Mar 20, 2025

About ANRO

Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company in the United States. The company’s product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with bipolar depression (BPD). It develops ALTO-300, a small molecule melatonergic agonist and serotonergic antagonist with antidepressant properties which is in phase 2b clinical trial to treat patients with major depressive disorder (MDD); ALTO-101, a novel small molecule phosphodiesterase 4 inhibitor which is in phase 2 proof-...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Feb 2, 2024
• Country: United States
• Stock Exchange: NYSE
• Ticker Symbol: ANRO
• Website: https://www.altoneuroscience.com

Analyst Forecast

According to 5 analysts, the average rating for ANRO stock is "Strong Buy." The 12-month stock price forecast is $17.0, which is an increase of 571.94% from the latest price.

Price Target

$17.0

(571.94% upside)

Analyst Consensus: Strong Buy